HomeCompareEYES vs NOBL

EYES vs NOBL: Dividend Comparison 2026

EYES yields 48.31% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EYES wins by $338.1K in total portfolio value
10 years
EYES
EYES
● Live price
48.31%
Share price
$4.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$360.9K
Annual income
$71,162.95
Full EYES calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — EYES vs NOBL

📍 EYES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEYESNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EYES + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EYES pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EYES
Annual income on $10K today (after 15% tax)
$4,106.28/yr
After 10yr DRIP, annual income (after tax)
$60,488.51/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, EYES beats the other by $60,279.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EYES + NOBL for your $10,000?

EYES: 50%NOBL: 50%
100% NOBL50/50100% EYES
Portfolio after 10yr
$191.9K
Annual income
$35,704.56/yr
Blended yield
18.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EYES right now

EYES
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-1.9
Piotroski
3/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EYES buys
0
NOBL buys
0
No recent congressional trades found for EYES or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEYESNOBL
Forward yield48.31%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$360.9K$22.8K
Annual income after 10y$71,162.95$246.19
Total dividends collected$285.6K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EYES vs NOBL ($10,000, DRIP)

YearEYES PortfolioEYES Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$15,531$4,830.92$10,914$214.34+$4.6KEYES
2$23,630$7,012.02$11,897$218.63+$11.7KEYES
3$35,255$9,970.75$12,952$222.72+$22.3KEYES
4$51,625$13,902.68$14,086$226.62+$37.5KEYES
5$74,266$19,026.49$15,302$230.33+$59.0KEYES
6$105,044$25,579.93$16,607$233.85+$88.4KEYES
7$146,212$33,814.22$18,007$237.18+$128.2KEYES
8$200,433$43,987.07$19,508$240.35+$180.9KEYES
9$270,818$56,354.64$21,116$243.35+$249.7KEYES
10$360,939$71,162.95$22,841$246.19+$338.1KEYES

EYES vs NOBL: Complete Analysis 2026

EYESStock

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Full EYES Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this EYES vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EYES vs SCHDEYES vs JEPIEYES vs OEYES vs KOEYES vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.